1
|
Krajacich BJ, Samaké D, Dao A, Diallo M, Sanogo ZL, Yaro AS, Zeguime A, Poudiougo J, Cissé K, Traoré M, dit Assitoun A, Faiman R, Zaidi I, Woodford J, Duffy PE, Lehmann T. Tracking SARS-CoV-2 seropositivity in rural communities using blood-fed mosquitoes: a proof-of-concept study. FRONTIERS IN EPIDEMIOLOGY 2023; 3:1243691. [PMID: 38455906 PMCID: PMC10911011 DOI: 10.3389/fepid.2023.1243691] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 06/21/2023] [Accepted: 11/17/2023] [Indexed: 03/09/2024]
Abstract
Background The spread of SARS-CoV-2 cannot be well monitored and understood in areas without capacity for effective disease surveillance. Countries with a young population will have disproportionately large numbers of asymptomatic or pauci-symptomatic infections, further hindering detection of infection. Sero-surveillance on a country-wide scale by trained medical professionals may be limited in a resource-limited setting such as Mali. Novel ways of broadly sampling the human population in a non-invasive method would allow for large-scale surveillance at a reduced cost. Approach Here we evaluate the collection of naturally blood-fed mosquitoes to test for human anti-SARS-CoV-2 antibodies in the laboratory and at five field locations in Mali. Results Immunoglobulin-G antibodies to multiple SARS-CoV-2 antigens were readily detected in mosquito bloodmeals by bead-based immunoassay through at least 10 h after feeding [mean sensitivity of 0.92 (95% CI 0.78-1) and mean specificity of 0.98 (95% CI 0.88-1)], indicating that most blood-fed mosquitoes collected indoors during early morning hours (and likely to have fed the previous night) are viable samples for analysis. We found that reactivity to four SARS-CoV-2 antigens rose during the pandemic from pre-pandemic levels. The crude seropositivity of blood sampled via mosquitoes was 6.3% in October and November 2020 across all sites, and increased to 25.1% overall by February 2021, with the most urban site reaching 46.7%, consistent with independent venous blood-based sero-surveillance estimates. Conclusions We have demonstrated that using mosquito bloodmeals, country-wide sero-surveillance of human diseases (both vector-borne and non-vector-borne) is possible in areas where human-biting mosquitoes are common, offering an informative, cost-effective, and non-invasive sampling option.
Collapse
Affiliation(s)
| | - Djibril Samaké
- Malaria Research and Training Center (MRTC)/Faculty of Medicine, Pharmacy and Odonto-Stomatology, University of Sciences, Techniques and Technologies, Bamako, Mali
| | - Adama Dao
- Malaria Research and Training Center (MRTC)/Faculty of Medicine, Pharmacy and Odonto-Stomatology, University of Sciences, Techniques and Technologies, Bamako, Mali
| | - Moussa Diallo
- Malaria Research and Training Center (MRTC)/Faculty of Medicine, Pharmacy and Odonto-Stomatology, University of Sciences, Techniques and Technologies, Bamako, Mali
| | - Zana Lamissa Sanogo
- Malaria Research and Training Center (MRTC)/Faculty of Medicine, Pharmacy and Odonto-Stomatology, University of Sciences, Techniques and Technologies, Bamako, Mali
| | - Alpha Seydou Yaro
- Malaria Research and Training Center (MRTC)/Faculty of Medicine, Pharmacy and Odonto-Stomatology, University of Sciences, Techniques and Technologies, Bamako, Mali
| | - Amatigue Zeguime
- Malaria Research and Training Center (MRTC)/Faculty of Medicine, Pharmacy and Odonto-Stomatology, University of Sciences, Techniques and Technologies, Bamako, Mali
| | - Josué Poudiougo
- Malaria Research and Training Center (MRTC)/Faculty of Medicine, Pharmacy and Odonto-Stomatology, University of Sciences, Techniques and Technologies, Bamako, Mali
| | - Kadiatou Cissé
- Malaria Research and Training Center (MRTC)/Faculty of Medicine, Pharmacy and Odonto-Stomatology, University of Sciences, Techniques and Technologies, Bamako, Mali
| | - Mamadou Traoré
- Malaria Research and Training Center (MRTC)/Faculty of Medicine, Pharmacy and Odonto-Stomatology, University of Sciences, Techniques and Technologies, Bamako, Mali
| | - Alassane dit Assitoun
- Malaria Research and Training Center (MRTC)/Faculty of Medicine, Pharmacy and Odonto-Stomatology, University of Sciences, Techniques and Technologies, Bamako, Mali
| | - Roy Faiman
- Laboratory of Malaria and Vector Research, NIAID, NIH, Rockville, MD, United States
| | - Irfan Zaidi
- Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
| | - John Woodford
- Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
| | - Patrick E. Duffy
- Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
| | - Tovi Lehmann
- Laboratory of Malaria and Vector Research, NIAID, NIH, Rockville, MD, United States
| |
Collapse
|
2
|
Krajacich BJ, Samaké D, Dao A, Diallo M, Sanogo ZL, Yaro AS, Ziguimé A, Poudiougo J, Cissé K, Traoré M, Assitoun AD, Faiman R, Zaidi I, John W, Duffy P, Lehmann T. Tracking SARS-CoV-2 seropositivity in rural communities using blood-fed mosquitoes. MEDRXIV : THE PREPRINT SERVER FOR HEALTH SCIENCES 2023:2023.06.13.23291267. [PMID: 37398491 PMCID: PMC10312890 DOI: 10.1101/2023.06.13.23291267] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 07/04/2023]
Abstract
The spread of SARS-CoV-2 cannot be well monitored and understood in areas without capacity for effective disease surveillance. Countries with a young population will have disproportionately large numbers of asymptomatic or pauci-symptomatic infections, further hindering detection of infection in the population. Sero-surveillance on a country-wide scale by trained medical professionals may be limited in scope in resource limited setting such as Mali. Novel ways of broadly sampling the human population in a non-invasive method would allow for large-scale surveillance at a reduced cost. Here we evaluate the collection of naturally bloodfed mosquitoes to test for human anti-SARS-CoV-2 antibodies in the laboratory and at five field locations in Mali. Immunoglobulin-G antibodies were found to be readily detectable within the mosquito bloodmeals by a bead-based immunoassay at least through 10 hours post-feeding with high sensitivity (0.900 ± 0.059) and specificity (0.924 ± 0.080), respectively, indicating that most blood-fed mosquitoes collected indoors during early morning hours (and thus, have likely fed the previous night) are viable samples for analysis. We find that reactivity to four SARS-CoV-2 antigens rose during the pandemic from pre-pandemic levels. Consistent with other sero-surveillance studies in Mali, crude seropositivity of blood sampled via mosquitoes was 6.3% in October/November 2020 over all sites, and increased to 25.1% overall, with the town closest to Bamako reaching 46.7% in February of 2021. Mosquito bloodmeals a viable target for conventional immunoassays, and therefore country-wide sero-surveillance of human diseases (both vector-borne and non-vector-borne) is attainable in areas where human-biting mosquitoes are common, and is an informative, cost-effective, non-invasive sampling option.
Collapse
Affiliation(s)
| | - Djibril Samaké
- Malaria Research and Training Center (MRTC)/ Faculty of Medicine, Pharmacy and Odontostomatology, University of Sciences, Techniques and Technologies, Bamako, Mali
| | - Adama Dao
- Malaria Research and Training Center (MRTC)/ Faculty of Medicine, Pharmacy and Odontostomatology, University of Sciences, Techniques and Technologies, Bamako, Mali
| | - Moussa Diallo
- Malaria Research and Training Center (MRTC)/ Faculty of Medicine, Pharmacy and Odontostomatology, University of Sciences, Techniques and Technologies, Bamako, Mali
| | - Zana Lamissa Sanogo
- Malaria Research and Training Center (MRTC)/ Faculty of Medicine, Pharmacy and Odontostomatology, University of Sciences, Techniques and Technologies, Bamako, Mali
| | - Alpha Seydou Yaro
- Malaria Research and Training Center (MRTC)/ Faculty of Medicine, Pharmacy and Odontostomatology, University of Sciences, Techniques and Technologies, Bamako, Mali
| | - Amatigué Ziguimé
- Malaria Research and Training Center (MRTC)/ Faculty of Medicine, Pharmacy and Odontostomatology, University of Sciences, Techniques and Technologies, Bamako, Mali
| | - Josué Poudiougo
- Malaria Research and Training Center (MRTC)/ Faculty of Medicine, Pharmacy and Odontostomatology, University of Sciences, Techniques and Technologies, Bamako, Mali
| | - Kadiatou Cissé
- Malaria Research and Training Center (MRTC)/ Faculty of Medicine, Pharmacy and Odontostomatology, University of Sciences, Techniques and Technologies, Bamako, Mali
| | - Mamadou Traoré
- Malaria Research and Training Center (MRTC)/ Faculty of Medicine, Pharmacy and Odontostomatology, University of Sciences, Techniques and Technologies, Bamako, Mali
| | - Alassane dit Assitoun
- Malaria Research and Training Center (MRTC)/ Faculty of Medicine, Pharmacy and Odontostomatology, University of Sciences, Techniques and Technologies, Bamako, Mali
| | - Roy Faiman
- Laboratory of Malaria and Vector Research, NIAID, NIH, Rockville, Maryland, USA
| | - Irfan Zaidi
- Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
| | - Woodford John
- Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
| | - Patrick Duffy
- Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
| | - Tovi Lehmann
- Laboratory of Malaria and Vector Research, NIAID, NIH, Rockville, Maryland, USA
| |
Collapse
|
3
|
Benabdessalem C, Hamouda WB, Marzouki S, Faye R, Mbow AA, Diouf B, Ndiaye O, Dia N, Faye O, Sall AA, Diagne CT, Amellal H, Ezzikouri S, Mioramalala DJN, Randrianarisaona F, Trabelsi K, Boumaiza M, Hamouda SB, Ouni R, Bchiri S, Chaaban A, Gdoura M, Gorgi Y, Sfar I, Yalaoui S, Khelil JB, Hamzaoui A, Abdallah M, Cherif Y, Petres S, Mok CKP, Escriou N, Quesney S, Dellagi K, Schoenhals M, Sarih M, Vigan-Womas I, Bettaieb J, Rourou S, Barbouche MR, Ahmed MB. Development and comparative evaluation of SARS-CoV-2 S-RBD and N based ELISA tests in various African endemic settings. Diagn Microbiol Infect Dis 2023; 105:115903. [PMID: 36805620 PMCID: PMC9867841 DOI: 10.1016/j.diagmicrobio.2023.115903] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2022] [Revised: 01/08/2023] [Accepted: 01/18/2023] [Indexed: 01/23/2023]
Abstract
Management of the COVID-19 pandemic relies on molecular diagnostic methods supported by serological tools. Herein, we developed S-RBD- and N- based ELISA assays useful for infection rate surveillance as well as the follow-up of acquired protective immunity against SARS-CoV-2. ELISA assays were optimized using COVID-19 Tunisian patients' sera and prepandemic controls. Assays were further validated in 3 African countries with variable endemic settings. The receiver operating curve was used to evaluate the assay performances. The N- and S-RBD-based ELISA assays performances, in Tunisia, were very high (AUC: 0.966 and 0.98, respectively, p < 0.0001). Cross-validation analysis showed similar performances in different settings. Cross-reactivity, with malaria infection, against viral antigens, was noticed. In head-to-head comparisons with different commercial assays, the developed assays showed high agreement. This study demonstrates, the added value of the developed serological assays in low-income countries, particularly in ethnically diverse populations with variable exposure to local endemic infectious diseases.
Collapse
Affiliation(s)
- Chaouki Benabdessalem
- Laboratory of Transmission, Control and Immunobiology of Infection, Institut Pasteur de Tunis, Tunisia; University Tunis El Manar, Tunis, Tunisia.
| | - Wafa Ben Hamouda
- Laboratory of Transmission, Control and Immunobiology of Infection, Institut Pasteur de Tunis, Tunisia; University Tunis El Manar, Tunis, Tunisia
| | - Soumaya Marzouki
- Laboratory of Transmission, Control and Immunobiology of Infection, Institut Pasteur de Tunis, Tunisia; University Tunis El Manar, Tunis, Tunisia
| | | | | | | | | | - Ndongo Dia
- Institut Pasteur de Dakar, Dakar, Senegal
| | | | | | | | - Houda Amellal
- Department of Parasitology and Vectorial Diseases. Institut Pasteur du Maroc. Casablanca. Morocco
| | - Sayeh Ezzikouri
- Department of Parasitology and Vectorial Diseases. Institut Pasteur du Maroc. Casablanca. Morocco
| | | | | | - Khaled Trabelsi
- University Tunis El Manar, Tunis, Tunisia; Laboratory of Molecular Microbiology, Vaccinology, and Biotechnological Development, Institut Pasteur de Tunis, Tunis, Tunisia
| | - Mohamed Boumaiza
- University Tunis El Manar, Tunis, Tunisia; Laboratory of Molecular Microbiology, Vaccinology, and Biotechnological Development, Institut Pasteur de Tunis, Tunis, Tunisia
| | - Sonia Ben Hamouda
- Laboratory of Transmission, Control and Immunobiology of Infection, Institut Pasteur de Tunis, Tunisia; University Tunis El Manar, Tunis, Tunisia
| | - Rym Ouni
- Laboratory of Transmission, Control and Immunobiology of Infection, Institut Pasteur de Tunis, Tunisia; University Tunis El Manar, Tunis, Tunisia
| | - Soumaya Bchiri
- Laboratory of Transmission, Control and Immunobiology of Infection, Institut Pasteur de Tunis, Tunisia; University Tunis El Manar, Tunis, Tunisia
| | - Amani Chaaban
- University Tunis El Manar, Tunis, Tunisia; Laboratory of Molecular Microbiology, Vaccinology, and Biotechnological Development, Institut Pasteur de Tunis, Tunis, Tunisia
| | - Mariem Gdoura
- Laboratory of Clinical Virology, Institut Pasteur de Tunis, Tunis, Tunisia
| | - Yousr Gorgi
- University Tunis El Manar, Tunis, Tunisia; Laboratory of Immunology, Charles Nicolle Hospital, Tunis, Tunisia
| | - Imen Sfar
- University Tunis El Manar, Tunis, Tunisia; Laboratory of Immunology, Charles Nicolle Hospital, Tunis, Tunisia
| | - Sadok Yalaoui
- University Tunis El Manar, Tunis, Tunisia; Laboratory of Immunology, Abderrahmen Mami University Hospital, Ariana, Tunisia
| | - Jalila Ben Khelil
- University Tunis El Manar, Tunis, Tunisia; Intensive care unit, Abderrahmen Mami University Hospital, Ariana, Tunisia
| | - Agnes Hamzaoui
- University Tunis El Manar, Tunis, Tunisia; Pneumology Department Abderrahmen Mami University Hospital, Ariana, Tunisia
| | - Meya Abdallah
- University Tunis El Manar, Tunis, Tunisia; Department of internal Medicine, Yasminette Hospital, Ben Arous, Tunisia
| | - Yosra Cherif
- University Tunis El Manar, Tunis, Tunisia; Department of internal Medicine, Yasminette Hospital, Ben Arous, Tunisia
| | | | - Chris Ka Pun Mok
- HKU-Pasteur Research Pole, School of Public Health, University of Hong Kong, Hong Kong; The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong
| | | | | | - Koussay Dellagi
- Institut Pasteur de Paris, Paris, France; Pasteur Network, Institut Pasteur, Paris, France
| | - Matthieu Schoenhals
- Immunology of Infectious Diseases, Institut Pasteur of Madagascar, Antananarivo, Madagascar
| | - M'hammed Sarih
- Department of Parasitology and Vectorial Diseases. Institut Pasteur du Maroc. Casablanca. Morocco
| | | | - Jihene Bettaieb
- Laboratory of Transmission, Control and Immunobiology of Infection, Institut Pasteur de Tunis, Tunisia; University Tunis El Manar, Tunis, Tunisia
| | - Samia Rourou
- University Tunis El Manar, Tunis, Tunisia; Laboratory of Molecular Microbiology, Vaccinology, and Biotechnological Development, Institut Pasteur de Tunis, Tunis, Tunisia
| | - Mohamed Ridha Barbouche
- Laboratory of Transmission, Control and Immunobiology of Infection, Institut Pasteur de Tunis, Tunisia; University Tunis El Manar, Tunis, Tunisia; Department of Microbiology, Immunology, and infectious diseases. College of Medicine and Medical sciences, Arabian Gulf University, Manama, Bahrain
| | - Melika Ben Ahmed
- Laboratory of Transmission, Control and Immunobiology of Infection, Institut Pasteur de Tunis, Tunisia; University Tunis El Manar, Tunis, Tunisia
| |
Collapse
|
4
|
Iriemenam NC, Ige FA, Greby SM, Okunoye OO, Uwandu M, Aniedobe M, Nwaiwu SO, Mba N, Okoli M, William NE, Ehoche A, Mpamugo A, Mitchell A, Stafford KA, Thomas AN, Olaleye T, Akinmulero OO, Agala NP, Abubakar AG, Owens A, Gwyn SE, Rogier E, Udhayakumar V, Steinhardt LC, Martin DL, Okoye MI, Audu R. Comparison of one single-antigen assay and three multi-antigen SARS-CoV-2 IgG assays in Nigeria. JOURNAL OF CLINICAL VIROLOGY PLUS 2023; 3:100139. [PMID: 36683611 PMCID: PMC9837382 DOI: 10.1016/j.jcvp.2023.100139] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2022] [Revised: 11/03/2022] [Accepted: 01/12/2023] [Indexed: 01/14/2023] Open
Abstract
Objectives Determining an accurate estimate of SARS-CoV-2 seroprevalence has been challenging in African countries where malaria and other pathogens are endemic. We compared the performance of one single-antigen assay and three multi-antigen SARS-CoV-2 IgG assays in a Nigerian population endemic for malaria. Methods De-identified plasma specimens from SARS-CoV-2 RT-PCR positive, dried blood spot (DBS) SARS-CoV-2 RT-PCR positive, and pre-pandemic negatives were used to evaluate the performance of the four SARS-CoV-2 assays (Tetracore, SARS2MBA, RightSign, xMAP). Results Results showed higher sensitivity with the multi-antigen (81% (Tetracore), 96% (SARS2MBA), 85% (xMAP)) versus the single-antigen (RightSign (64%)) SARS-CoV-2 assay. The overall specificities were 98% (Tetracore), 100% (SARS2MBA and RightSign), and 99% (xMAP). When stratified based on <15 days to ≥15 days post-RT-PCR confirmation, the sensitivities increased from 75% to 88.2% for Tetracore; from 93% to 100% for the SARS2MBA; from 58% to 73% for RightSign; and from 83% to 88% for xMAP. With DBS, there was no positive increase after 15-28 days for the three assays (Tetracore, SARS2MBA, and xMAP). Conclusion Multi-antigen assays performed well in Nigeria, even with samples with known malaria reactivity, and might provide more accurate measures of COVID-19 seroprevalence and vaccine efficacy.
Collapse
Affiliation(s)
- Nnaemeka C Iriemenam
- Division of Global HIV and TB, Center for Global Health, Centers for Disease Control and Prevention, Abuja, Nigeria
| | - Fehintola A Ige
- Center for Human Virology and Genomics, Microbiology Department, Nigerian Institute of Medical Research, Yaba, Lagos, Nigeria
| | - Stacie M Greby
- Division of Global HIV and TB, Center for Global Health, Centers for Disease Control and Prevention, Abuja, Nigeria
| | - Olumide O Okunoye
- Division of Global HIV and TB, Center for Global Health, Centers for Disease Control and Prevention, Abuja, Nigeria
| | - Mabel Uwandu
- Center for Human Virology and Genomics, Microbiology Department, Nigerian Institute of Medical Research, Yaba, Lagos, Nigeria
| | - Maureen Aniedobe
- Center for Human Virology and Genomics, Microbiology Department, Nigerian Institute of Medical Research, Yaba, Lagos, Nigeria
| | - Stephnie O Nwaiwu
- Center for Human Virology and Genomics, Microbiology Department, Nigerian Institute of Medical Research, Yaba, Lagos, Nigeria
| | - Nwando Mba
- Nigeria Centre for Disease Control (NCDC), Gaduwa, FCT, Nigeria
| | - Mary Okoli
- Nigeria Centre for Disease Control (NCDC), Gaduwa, FCT, Nigeria
| | | | - Akipu Ehoche
- University of Maryland Center for International Health, Education, and Biosecurity (CIHEB), Maryland Global Initiatives Corporation (MGIC), FCT, Nigeria
| | - Augustine Mpamugo
- University of Maryland Center for International Health, Education, and Biosecurity (CIHEB), Maryland Global Initiatives Corporation (MGIC), FCT, Nigeria
| | - Andrew Mitchell
- Center for International Health, Education, and Biosecurity, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, USA
| | - Kristen A Stafford
- Center for International Health, Education, and Biosecurity, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, USA
| | - Andrew N Thomas
- International Research Center of Excellence, Institute of Human Virology, Abuja, Nigeria
| | - Temitope Olaleye
- International Research Center of Excellence, Institute of Human Virology, Abuja, Nigeria
| | - Oluwaseun O Akinmulero
- International Research Center of Excellence, Institute of Human Virology, Abuja, Nigeria
| | - Ndidi P Agala
- International Research Center of Excellence, Institute of Human Virology, Abuja, Nigeria
| | - Ado G Abubakar
- International Research Center of Excellence, Institute of Human Virology, Abuja, Nigeria
| | - Ajile Owens
- Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - Sarah E Gwyn
- Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - Eric Rogier
- Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - Venkatachalam Udhayakumar
- Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - Laura C Steinhardt
- Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - Diana L Martin
- Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - McPaul I Okoye
- Division of Global HIV and TB, Center for Global Health, Centers for Disease Control and Prevention, Abuja, Nigeria
| | - Rosemary Audu
- Center for Human Virology and Genomics, Microbiology Department, Nigerian Institute of Medical Research, Yaba, Lagos, Nigeria
| |
Collapse
|
5
|
Sereti I, Shaw-Saliba K, Dodd LE, Dewar RL, Laverdure S, Brown S, Mbaya OT, Muyembe Tamfum JJ, Mblala-Kingebeni P, Sow Y, Akpa E, Haidara MC, Fouth Tchos K, Beavogui AH, Neal A, Arlinda D, Lokida D, Grue L, Smolskis M, McNay LA, Gayedyu-Dennis D, Ruiz-Palacios GM, Montenegro-Liendo A, Tounkara M, Samake S, Jargalsaikhan G, Zulkhuu D, Weyers S, Bonnett T, Potter GE, Stevens R, Rupert A, Aboulhab J, Biampata JL, Delamo A, Camara BS, Kosasih Indonesia H, Karyana M, Duworko JT, Regalado-Pineda J, Guerra-de-Blas PDC, Doumbia S, Dabitao D, Dashdorj N, Dashdorj N, Newell K, Francis A, Rubenstein K, Bera V, Gulati I, Sardana R, Millard M, Ridzon R, Hunsberger S. Design of an observational multi-country cohort study to assess immunogenicity of multiple vaccine platforms (InVITE). PLoS One 2022; 17:e0273914. [PMID: 36107966 PMCID: PMC9477293 DOI: 10.1371/journal.pone.0273914] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2022] [Accepted: 07/19/2022] [Indexed: 11/19/2022] Open
Abstract
In response to the COVID-19 pandemic, COVID-19 vaccines have been developed, and the World Health Oraganization (WHO) has granted emergency use listing to multiple vaccines. Studies of vaccine immunogenicity data from implementing COVID-19 vaccines by national immunization programs in single studies spanning multiple countries and continents are limited but critically needed to answer public health questions on vaccines, such as comparing immune responses to different vaccines and among different populations.
Collapse
Affiliation(s)
- Irini Sereti
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States of America
| | - Kathryn Shaw-Saliba
- Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States of America
| | - Lori E. Dodd
- Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States of America
| | - Robin L. Dewar
- Virus Isolation and Serology Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America
| | - Sylvain Laverdure
- Laboratory of Human Retrovirology and Immunoinformatics, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America
| | - Shawn Brown
- AIDS Monitoring Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America
| | - Olivier Tshiani Mbaya
- Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America
| | | | | | - Ydrissa Sow
- Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States of America
| | - Esther Akpa
- Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States of America
| | - Mory Cherif Haidara
- Centre National de Formation et de Recherche en Santé Rurale de Maferinyah, Maférinya, Guinea
| | - Karine Fouth Tchos
- Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States of America
| | - Abdoul Habib Beavogui
- Centre National de Formation et de Recherche en Santé Rurale de Maferinyah, Maférinya, Guinea
| | - Aaron Neal
- Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States of America
| | | | - Dewi Lokida
- Indonesia Research Partnership on Infectious Diseases National Institute of Health Research and Development, Jakarta, Indonesia
| | - Louis Grue
- Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America
| | - Mary Smolskis
- Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States of America
| | - Laura A. McNay
- Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States of America
| | | | - Guillermo M. Ruiz-Palacios
- Departamento de Infectología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico
| | | | - Moctar Tounkara
- University Clinical Research Center, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - Seydou Samake
- University Clinical Research Center, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | | | | | - Shera Weyers
- Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America
| | - Tyler Bonnett
- Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America
| | - Gail E. Potter
- Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States of America
| | - Randy Stevens
- AIDS Monitoring Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America
| | - Adam Rupert
- AIDS Monitoring Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America
| | - Jamila Aboulhab
- Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States of America
| | - Jean-Luc Biampata
- Institut National de Recherche Biomedicale, Kinshasa, Democratic Republic of Congo
| | - Alexandre Delamo
- Centre National de Formation et de Recherche en Santé Rurale de Maferinyah, Maférinya, Guinea
| | - Bienvenu Salim Camara
- Centre National de Formation et de Recherche en Santé Rurale de Maferinyah, Maférinya, Guinea
| | - Herman Kosasih Indonesia
- Indonesia Research Partnership on Infectious Diseases National Institute of Health Research and Development, Jakarta, Indonesia
| | | | - James T. Duworko
- Partnership for Research on Vaccines and Infectious Diseases in Liberia, Monrovia, Liberia
| | - Justino Regalado-Pineda
- Subdirección de Medicina, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Ciudad de México, Mexico
| | | | - Seydou Doumbia
- University Clinical Research Center, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - Djeneba Dabitao
- University Clinical Research Center, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | | | | | - Kevin Newell
- Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America
| | - Alyson Francis
- Systex, Inc, Rockville, Maryland, United States of America
| | - Kevin Rubenstein
- Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America
| | - Victoria Bera
- Systex, Inc, Rockville, Maryland, United States of America
| | - Iman Gulati
- Systex, Inc, Rockville, Maryland, United States of America
| | - Ratna Sardana
- Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States of America
| | - Monica Millard
- Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America
| | - Renee Ridzon
- Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States of America
| | - Sally Hunsberger
- Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States of America
| |
Collapse
|
6
|
Woodford J, Sagara I, Diawara H, Assadou MH, Katile A, Attaher O, Issiaka D, Santara G, Soumbounou IH, Traore S, Traore M, Dicko OM, Niambele SM, Mahamar A, Kamate B, Haidara B, Sissoko K, Sankare S, Diarra SDK, Zeguime A, Doritchamou JYA, Zaidi I, Dicko A, Duffy PE. Recent malaria does not substantially impact COVID-19 antibody response or rates of symptomatic illness in communities with high malaria and COVID-19 transmission in Mali, West Africa. Front Immunol 2022; 13:959697. [PMID: 35990648 PMCID: PMC9382593 DOI: 10.3389/fimmu.2022.959697] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2022] [Accepted: 06/29/2022] [Indexed: 11/13/2022] Open
Abstract
Malaria has been hypothesized as a factor that may have reduced the severity of the COVID-19 pandemic in sub-Saharan Africa. To evaluate the effect of recent malaria on COVID-19 we assessed a subgroup of individuals participating in a longitudinal cohort COVID-19 serosurvey that were also undergoing intensive malaria monitoring as part of antimalarial vaccine trials during the 2020 transmission season in Mali. These communities experienced a high incidence of primarily asymptomatic or mild COVID-19 during 2020 and 2021. In 1314 individuals, 711 were parasitemic during the 2020 malaria transmission season; 442 were symptomatic with clinical malaria and 269 had asymptomatic infection. Presence of parasitemia was not associated with new COVID-19 seroconversion (29.7% (211/711) vs. 30.0% (181/603), p=0.9038) or with rates of reported symptomatic seroconversion during the malaria transmission season. In the subsequent dry season, prior parasitemia was not associated with new COVID-19 seroconversion (30.2% (133/441) vs. 31.2% (108/346), p=0.7499), with symptomatic seroconversion, or with reversion from seropositive to seronegative (prior parasitemia: 36.2% (64/177) vs. no parasitemia: 30.1% (37/119), p=0.3842). After excluding participants with asymptomatic infection, clinical malaria was also not associated with COVID-19 serostatus or symptomatic seroconversion when compared to participants with no parasitemia during the monitoring period. In communities with intense seasonal malaria and a high incidence of asymptomatic or mild COVID-19, we did not demonstrate a relationship between recent malaria and subsequent response to COVID-19. Lifetime exposure, rather than recent infection, may be responsible for any effect of malaria on COVID-19 severity.
Collapse
Affiliation(s)
- John Woodford
- Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, Bethesda, MD, United States
| | - Issaka Sagara
- Malaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali
| | - Halimatou Diawara
- Malaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali
| | - Mahamadoun Hamady Assadou
- Malaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali
| | - Abdoulaye Katile
- Malaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali
| | - Oumar Attaher
- Malaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali
| | - Djibrilla Issiaka
- Malaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali
| | - Gaoussou Santara
- Malaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali
| | - Ibrahim H Soumbounou
- Malaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali
| | - Seydou Traore
- Malaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali
| | - Moussa Traore
- Malaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali
| | - Oumar M Dicko
- Malaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali
| | - Sidi Mohamed Niambele
- Malaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali
| | - Almahamoudou Mahamar
- Malaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali
| | - Bourama Kamate
- Malaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali
| | - Bayaya Haidara
- Malaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali
| | - Kourane Sissoko
- Malaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali
| | - Seydou Sankare
- Malaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali
| | - Sadio Dite Koni Diarra
- Malaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali
| | - Amatigue Zeguime
- Malaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali
| | - Justin Y A Doritchamou
- Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, Bethesda, MD, United States
| | - Irfan Zaidi
- Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, Bethesda, MD, United States
| | - Alassane Dicko
- Malaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali
| | - Patrick E Duffy
- Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, Bethesda, MD, United States
| |
Collapse
|
7
|
Woodford J, Sagara I, Dicko A, Duffy PE. Adapting malaria clinical trials infrastructure to implement COVID-19 epidemiology studies: Response to a public health emergency amid safe continuation of a research enterprise. Front Public Health 2022; 10:959678. [PMID: 35958840 PMCID: PMC9358281 DOI: 10.3389/fpubh.2022.959678] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2022] [Accepted: 07/06/2022] [Indexed: 12/01/2022] Open
Affiliation(s)
- John Woodford
- Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, Bethesda, MD, United States
- *Correspondence: John Woodford
| | - Issaka Sagara
- Malaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali
| | - Alassane Dicko
- Malaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali
| | - Patrick E. Duffy
- Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, Bethesda, MD, United States
| |
Collapse
|